For about 5 years, the standard first-line treatment of advanced NSCLC harboring EGFR mutations, specifically Ex19del and L858R, has further changed and improved with the approval of osimertinib, an oral third-generation, irreversible but selective, EGFR–TKI [8,9]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.